NEW YORK (GenomeWeb News) – BG Medicine today reported second quarter revenues of $799,000, down 20 percent from $1.0 million in the second quarter of 2013.

The revenues consisted solely of product revenues from sales of the company's BGM Galectin-3 test. Product revenues were down 18 percent from $972,000 in Q2 2013.

The company reported no service revenues. It reported $34,000 in service revenues in the year-ago period.

BG also lowered its full-year 2014 guidance, noting that it no longer expects 2014 revenues to exceed 2013 revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.